These results suggest that CD11b modulation via pharmacologic and genetic approaches similarly changes the immune phenotype within the TME to augment anti-tumor immune responses and suggests that T cell mediated immunity may be partly responsible for controlling tumor growth. This evidence concerns the gene ITGAM and neoplasm.